ClinicalTrials.gg
CompletedNCT00418665Updated Jan 24, 2011Results posted

A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

A Phase 2 interventional study of AMG 531 and Placebo in Myelodysplastic Syndromes and Thrombocytopenia, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by Amgen · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Myelodysplastic Syndromes by Amgen — none open to participants now, none under way, none of them phase 3. Myelodysplastic Syndromes · Amgen.

Enrollment
8th of 11
39 · median 72
Started
2006
with 2 others
Phase 2
5 of 11
none open now
Registered
4th of 11
by date

Among the 11 studies in Myelodysplastic Syndromes by Amgen, this one is the 8th largest by enrollment, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 4th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 11 studies in Myelodysplastic Syndromes by Amgen is open now. The open studies under Myelodysplastic Syndromes, anywhere →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Myelodysplastic Syndromes by Amgen as a file.
02

Study summary

This is a dose and schedule finding study of AMG 531 designed to assess the activity of AMG 531 to reduce the rate of clinically significant bleeding and blood transfusions in subjects with myelodysplastic syndrome (MDS) receiving lenalidomide. Subjects with MDS that are planned to receive at least four cycles of lenalidomide for treatment of their disease are appropriate to screen for this study.

All subjects meeting the eligibility criteria will receive lenalidomide 10 mg capsule by mouth daily every day of each 28-day cycle. Subjects will receive AMG 531 or placebo once a week by subcutaneous injection for 16 weeks.

03

Conditions studied

  • Myelodysplastic Syndromes
  • Thrombocytopenia

Keywords

  • Revlimid
  • Lenalidomide
  • Low Platelet Count
  • Low Risk Myelodysplastic Syndrome
  • Intermediate 1 Myelodysplastic Syndrome
  • MDS
  • Myelodysplastic Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MDS by bone marrow based on the World Health Organization (WHO) classification
  • Low or Intermediate-1 risk category MDS using the IPSS
  • Planned to receive lenalidomide 10 mg capsule by mouth daily for all 28 days of each cycle for at least 4 cycles
  • Eastern Cooperative Oncology () performance status of 0-2
  • Subjects must be at least 18 years of age or older

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to >3 cycles of lenalidomide
  • Exposure to lenalidomide within the last 30 days
  • Prior history of leukemia or aplastic anemia
  • Prior history of stem cell transplantation
  • Prior (other than in situ cervical cancer or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for 3 years before randomization
  • Active or uncontrolled infections
  • Unstable angina, congestive heart failure [ > class II], uncontrolled hypertension [diastolic > 100 mmHg], uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction
  • History of arterial thrombosis ( eg, stroke or ) in the past year
  • History of venous thrombosis in the past year
  • Received IL-11 within 4 weeks of screening
  • Less than 4 weeks since receipt of any drug or device
  • Have previously received any other thrombopoietic growth factor
  • Pregnant or breast feeding
  • Subjects of who are not using adequate precautions, in the judgment of the investigator
  • Known to any recombinant E coli-derived product
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Active comparator
    750 mcg AMG 531

    750 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)

    Biological: AMG 531

  • Placebo comparator
    Placebo Part B

    Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)

    Drug: Placebo

  • Placebo comparator
    Placebo Part A

    Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)

    Drug: Placebo

  • Active comparator
    500 mcg AMG 531

    500 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)

    Biological: AMG 531

  • Active comparator
    750 mcg AMG531 Part B

    750 μg AMG 531 biweekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)

    Biological: AMG 531

Interventions

  • BiologicalAMG 531

    AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.

  • DrugPlacebo

    Subjects in the control group will receive placebo via subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Occurrence of a Clinically Significant Thrombocytopenic Event

    Occurrence of one or more clinically significant thrombocytopenic events, defined as either Common Terminology Criteria for Adverse Events (CTCAE) v. 3 grade 3 or 4 thrombocytopenia starting from week 3 of cycle 1 or receipt of platelet transfusions starting from week 1 of cycle 1 and continuing through the end of treatment visit.

    Time frame: Treatment period through interim follow-up visit (up to 16 weeks)

Secondary outcomes

  1. Lenalidomide Dose Reduction and Delay Due to Thrombocytopenia

    Occurrence of lenalidomide dose reduction and delay due to thrombocytopenia

    Time frame: Treatment period (up to 16 weeks)

  2. Achieving an Overall Response (Complete Response (CR) or Partial Response (PR)) Determined by the Investigator Based on Modified International Working Group 2006 Response Criteria Guidelines

    CR = decrease in bone marrow blast (≤5%) and improvement in peripheral blood counts (Hgb ≥ 11 g/dL, platelets ≥ 100x10\^9/L, neutrophils ≥ 1x10\^9/L, peripheral blasts=0%). PR = improvement in peripheral blood counts plus a decrease in bone marrow blasts ≥50% but not ≤5, or decrease in International Prognostic Scoring System score.

    Time frame: Treatment period and post-treatment follow-up (up to 21 weeks)

  3. Platelet Transfusion

    Occurrence of one or more platelet transfusions during the treatment period

    Time frame: Treatment period (up to 16 weeks)

07

Results

Posted Dec 22, 2010

Participant flow

Participants were enrolled from 14 March 2007 through 24 July 2008

Treatment Period
Participant flow — Treatment Period
MilestonePlaceboRomiplostim (AMG 531) 500 μgRomiplostim (AMG 531) 750 μg
Started121413
Received study medication111313
Completed789
Not completed564
Withdrew: Ineligibility determined110
Withdrew: Adverse event220
Withdrew: Withdrawal by subject031
Withdrew: Requirement for alternative therapy100
Withdrew: Physician decision103
Treatment Extension
Participant flow — Treatment Extension
MilestonePlaceboRomiplostim (AMG 531) 500 μgRomiplostim (AMG 531) 750 μg
Started789
Completed147
Not completed642
Withdrew: Adverse event100
Withdrew: Withdrawal by subject100
Withdrew: Requirement for alternative therapy220
Withdrew: Physician decision221
Withdrew: Death001

Outcome measures

PrimaryOccurrence of a Clinically Significant Thrombocytopenic Event

Occurrence of one or more clinically significant thrombocytopenic events, defined as either Common Terminology Criteria for Adverse Events (CTCAE) v. 3 grade 3 or 4 thrombocytopenia starting from week 3 of cycle 1 or receipt of platelet transfusions starting from week 1 of cycle 1 and continuing through the end of treatment visit.

Time frame:
Treatment period through interim follow-up visit (up to 16 weeks)
Reported as:
Number · Participants
Occurrence of a Clinically Significant Thrombocytopenic Event
ParticipantsPlaceboRomiplostim 500 μgRomiplostim 750 μg
Occurrence of a Clinically Significant Thrombocytopenic Event848
Statistical analysis
  • Placebo vs Romiplostim 750 μg · Odds ratio (or): 0.600 · 95% CI 0.070 to 5.136Romiplostim/placebo
  • Placebo vs Romiplostim 500 μg · Odds ratio (or): 0.154 · 95% CI 0.022 to 1.071Romiplostim/placebo
SecondaryLenalidomide Dose Reduction and Delay Due to Thrombocytopenia

Occurrence of lenalidomide dose reduction and delay due to thrombocytopenia

Time frame:
Treatment period (up to 16 weeks)
Reported as:
Number · Participants
Lenalidomide Dose Reduction and Delay Due to Thrombocytopenia
ParticipantsPlaceboRomiplostim 500 μgRomiplostim 750 μg
Lenalidomide Dose Reduction and Delay Due to Thrombocytopenia652
Statistical analysis
  • Placebo vs Romiplostim 750 μg · Odds ratio, log: 0.154 · 95% CI 0.022 to 1.071Romiplostim/placebo
  • Placebo vs Romiplostim 500 μg · Odds ratio (or): 0.514 · 95% CI 0.102 to 2.589Romiplostim/placebo
SecondaryAchieving an Overall Response (Complete Response (CR) or Partial Response (PR)) Determined by the Investigator Based on Modified International Working Group 2006 Response Criteria Guidelines

CR = decrease in bone marrow blast (≤5%) and improvement in peripheral blood counts (Hgb ≥ 11 g/dL, platelets ≥ 100x10\^9/L, neutrophils ≥ 1x10\^9/L, peripheral blasts=0%). PR = improvement in peripheral blood counts plus a decrease in bone marrow blasts ≥50% but not ≤5, or decrease in International Prognostic Scoring System score.

Time frame:
Treatment period and post-treatment follow-up (up to 21 weeks)
Reported as:
Number · Participants
Achieving an Overall Response (Complete Response (CR) or Partial Response (PR)) Determined by the Investigator Based on Modified International Working Group 2006 Response Criteria Guidelines
ParticipantsPlaceboRomiplostim 500 μgRomiplostim 750 μg
Achieving an Overall Response (Complete Response (CR) or Partial Response (PR)) Determined by the Investigator Based on Modified International Working Group 2006 Response Criteria Guidelines123
Statistical analysis
  • Placebo vs Romiplostim 750 μg · Odds ratio (or): 3.000 · 95% CI 0.227 to 39.608Romiplostim/placebo
  • Placebo vs Romiplostim 500 μg · Odds ratio (or): 1.714 · 95% CI 0.144 to 20.473Romiplostim/placebo
SecondaryPlatelet Transfusion

Occurrence of one or more platelet transfusions during the treatment period

Time frame:
Treatment period (up to 16 weeks)
Reported as:
Number · Participants
Platelet Transfusion
ParticipantsPlaceboRomiplostim 500 μgRomiplostim 750 μg
Platelet Transfusion444
Statistical analysis
  • Placebo vs Romiplostim 750 μg · Odds ratio (or): 0.911 · 95% CI 0.097 to 8.529Romiplostim/placebo
  • Placebo vs Romiplostim 500 μg · Odds ratio (or): 0.866 · 95% CI 0.175 to 4.278Romiplostim/placebo

Adverse events

Collected over Up to 21 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—6/9 (66.7%)8/9 (88.9%)
Romiplostim 500 µg—5/14 (35.7%)14/14 (100%)
Romiplostim 750 µg—4/14 (28.6%)14/14 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPlaceboRomiplostim 500 µgRomiplostim 750 µg
ThrombocytopeniaBlood and lymphatic system disorders0/93/141/14
AnaemiaBlood and lymphatic system disorders0/91/142/14
Back painMusculoskeletal and connective tissue disorders0/92/140/14
NeutropeniaBlood and lymphatic system disorders1/91/140/14
Angina pectorisCardiac disorders1/90/140/14
DiarrhoeaGastrointestinal disorders1/91/140/14
PyrexiaGeneral disorders1/90/140/14
BacteraemiaInfections and infestations1/90/140/14
CellulitisInfections and infestations1/90/140/14
ArthralgiaMusculoskeletal and connective tissue disorders1/90/140/14
Most frequent other events
Showing 10 of 137
Most frequent other events
EventPlaceboRomiplostim 500 µgRomiplostim 750 µg
FatigueGeneral disorders1/94/148/14
DiarrhoeaGastrointestinal disorders4/94/145/14
ConstipationGastrointestinal disorders0/95/141/14
NauseaGastrointestinal disorders0/93/145/14
Oedema peripheralGeneral disorders3/95/143/14
RashSkin and subcutaneous tissue disorders2/95/145/14
NeutropeniaBlood and lymphatic system disorders3/91/144/14
ThrombocytopeniaBlood and lymphatic system disorders3/94/142/14
DizzinessNervous system disorders3/92/141/14
InsomniaPsychiatric disorders0/94/141/14

Baseline characteristics

Age Continuous
Age Continuous(Years)PlaceboRomiplostim 500 μgRomiplostim 750 μgTotal
Mean73.2 ± 15.072.9 ± 11.466.7 ± 9.470.9 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomiplostim 500 μgRomiplostim 750 μgTotal
Female46515
Male88824
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRomiplostim 500 μgRomiplostim 750 μgTotal
White or Caucasian11131236
Black or African American0011
Hispanic or Latino1102
International Prognostic Scoring System (IPSS) Score
International Prognostic Scoring System (IPSS) Score(Participants)PlaceboRomiplostim 500 μgRomiplostim 750 μgTotal
044614
0.536413
1.03238
>1.01102
Missing1102
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol. 2012 Nov 29;5:71. doi: 10.1186/1756-8722-5-71. PubMed 23190430 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Mar 2009 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2007
First posted
Jan 5, 2007
Start
Dec 2006
Primary completionActual
Mar 2009
CompletionActual
Oct 2010
Results first posted
Dec 22, 2010
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00418665
Lead sponsor
Amgen
First posted
Jan 5, 2007
Start date
Dec 2006
Primary completion
Mar 2009
Completion
Oct 2010
Results posted
Dec 22, 2010
Last update
Jan 24, 2011

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion